Medication-Induced Psychosis

doi:10.1017/CBO9780511543784.023

22 - Medication-Induced Psychosis

from Part VI - Substance Abuse and Medications

Published online by Cambridge University Press: 06 January 2010

Junji Takeshita ,

Diane Thompson and

Stephen E. Nicolson

Edited by

Daryl Fujii and

Iqbal Ahmed

Show author details

Junji Takeshita: Affiliation:
University of Hawaii
Diane Thompson: Affiliation:
Queen's Medical Center
Stephen E. Nicolson: Affiliation:
Massachusetts General Hospital
Daryl Fujii: Affiliation:
University of Hawaii, Manoa
Iqbal Ahmed: Affiliation:
University of Hawaii, Manoa

Book contents

Get access

Summary

Medication-induced psychosis is a common occurrence. Both in and out of the hospital, patients with multiple health problems are at an increased risk of developing both psychosis and delirium with the addition of prescription and over-the-counter medications. This chapter will define medication-induced psychosis, differentiate this disorder from delirium, and discuss the drug classes most often associated with psychosis. Unlike many forms of psychosis, medication-induced psychosis does not have specific long-term psychiatric symptoms, prodromes, positive versus negative symptoms, common brain neuropathology, or genetic factors. It is neither gender specific nor age specific. The sole risk of medication-induced psychosis lies in a patient's general risk of developing a medical problem that requires the use of drug therapy.

Many medications when taken at therapeutic doses are associated with the development of psychotic symptoms (Anonymous, 2002). There are few large studies to substantiate these relationships; instead we must rely on case studies. Because many of these same medicines can also cause delirium (Trzepacz & Meagher, 2005), it is necessary to differentiate “delirium” from “psychosis” as there is obvious overlap between the disorders. Differentiating between drug-induced psychosis and delirium can be difficult. This distinction appears to be at least historically ambiguous if not controversial. Some texts group delirium in with “secondary psychoses” whose characteristic features of “clouding of consciousness” and “fluctuating course” differentiate them from primary psychoses. Charlton and Kavanau argue that most psychiatric conditions, including primary mental illness as well as intoxications have a delirious component to the disease (Charlton & Kavanau, 2002).

Type: Chapter
Information: The Spectrum of Psychotic Disorders
Neurobiology, Etiology and Pathogenesis
, pp. 406 - 452

DOI: https://doi.org/10.1017/CBO9780511543784.023 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Aderhold, R. M. & Muniz, C. E. (1970). Acute psychosis with amitriptyline and furazolidone. Journal of the American Medical Association, 213, 2080.Google Scholar

Ahmad, S. (1996). Losartan and reversible psychosis. Cardiology, 87, 569–70.Google Scholar

American Psychiatric Association (2000). Diagnosis and Statistical Manual of Mental Disorders. 4th edn, Text Revision. Washington, DC: American Psychiatric Association.

Anonymous (2002). Drugs that may cause psychiatric symptoms. Medical Letter on Drugs & Therapeutics, ed. Abramowicz, M., 44(1134), 59–62.

Apter, A., Ratzoni, G., King, R. A., et al. (1994). Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 342–8.Google Scholar

Baldessarini, R. J. & Willmuth, R. L. (1968). Psychotic reactions during amitriptyline therapy. Canadian Psychiatric Association Journal, 13, 571–3.Google Scholar

Barak, Y., Wohl, Y., Greenberg, Y., et al. (2005). Affective psychosis following accutane (isotretinoin) treatment. International Clinical Psychopharmacology, 20, 39–41.Google Scholar

Beeber, A. R. & Manring, J. M. Jr. (1983). Psychosis following cyclobenzaprine use. Journal of Clinical Psychiatry, 44, 151–2.Google Scholar

Bent, M. J., Bos, G. M., Sillevis Smitt, P. A., & Cornelissen, J. J. (1999). Erythropoietin induced visual hallucinations after bone marrow transplantation. Journal of Neurology, 246, 614–16.Google Scholar

Berger, M., White, J., Travis, L. B., et al. (1977). Toxic psychosis due to cyproheptadine in a child on hemodialysis: A case report. Clinical Nephrology, 7, 43–4.Google Scholar

Bessa, O. (1994). Acute psychosis due to indomethacin. Connecticut Medicine, 58(7), 395–6.Google Scholar

Bhatia, S. C., Arora, M., & Bhatia, S. K. (2001). Perceptual disturbances with zaleplon. Psychiatric Services, 52, 109–10.Google Scholar

Biswas, P. N., Wilton, L. V., & Shakir, S. A. (2003). The pharmacovigilance of mirtazapine: Results of a prescription event monitoring study on 13554 patients in England. Journal of Psychopharmacology, 17, 121–6.Google Scholar

Boyson, S. J. (1991). Psychiatric effects of selegiline, Archives of Neurology, 48, 902.Google Scholar

Breitbart, W., Marotta, R. F., & Call, P. (1988). AIDS and neuroleptic malignant syndrome. Lancet, 2(8626–7), 1488–9.Google Scholar

Brown, E. S. & Suppes, T. (1998). Mood symptoms during corticosteroid therapy: A review. Harvard Review Psychiatry, 5, 239–46.Google Scholar

Cancelli, I., Marcon, G., & Balestrieri, M. (2004). Factors associated with complex visual hallucinations during antidepressant treatment. Human Psychopharmacology, 19(8), 577–84.Google Scholar

Cantu, T. G. & Korek, J. S. (1991) Central nervous system reactions to histamine-2 receptor blockers. Annals of Internal Medicine, 114(12), 1027–34.Google Scholar

Capuron, L., Ravaud, A., & Dantzer, R. (2001). Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosomatic Medicine, 63(3), 376–86.Google Scholar

Capuron, L., Gumnick, J. F., Musselman, D. L., et al. (2002). Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology, 26, 643–52.Google Scholar

Catalano, G., Catalano, M. C., & Alberts, V. A. (1996). Famotidine-associated delirium. Psychosomatics, 37, 349–55.Google Scholar

Charlton, B. J. & Kavanau, J. L. (2002). Delirium and psychotic symptoms – an integrative model. Medical Hypotheses, 58, 24–7.Google Scholar

Chin, D. K. F., Cho, A. K., & Tse, C. Y. (1986). Neuropsychiatric complications related to use of prazosin in patients with renal failure. British Medical Journal, 293, 1347.Google Scholar

Chodorowski, Z., Sein Anand, J., & Wisniewski, M. (2004). Acute intoxication with baclofen. Przeglad Lekarski, 61(4), 389–91.Google Scholar

Christensen, R. C. (1995). Paroxetine-induced psychotic mania. American Journal of Psychiatry, 152, 1399–400.Google Scholar

Citrome, L., Levine, J., & Allingham, B. (2000). Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatric Services, 51, 634–8.Google Scholar

Coleman, D. E. & Ota, K. (2004). Hallucinations with zolpidem and fluoxetine in an impaired driver. Journal of Forensic Sciences, 49, 392–3.Google Scholar

Cummings, J. L. & Back, C. (1998). The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. 6, 64–78.

Cummings, J. L. & Kaufer, D. I. (1996). Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology, 47, 876–83.Google Scholar

Daniel, D. G., Swallows, A., & Wolff, F. (1987). Capgras delusion and seizures in association with therapeutic dosages of disulfram. Southern Medical Journal, 80, 1577–80.Google Scholar

Defromont, L., Portenart, C., & Couvez, A. (1999). Psychiatric side effects of non-steroidal anti-inflammatory agents. French Encephale, 25, 11–15.Google Scholar

Denicoff, K. D., Rubinow, D. R., Papa, M. Z., et al. (1987) The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-actived killer cells. Annals of Internal Medicine, 107, 293–300.Google Scholar

Devulder, J., Laat, M., Dumoulin, K., Renson, A., & Rolly, G. (1996). Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants. Acta Clinica Belgica, 51, 184–6.Google Scholar

Douglass, M. A. & Levine, D. P. (2000). Hallucinations in an elderly patient taking recommended doses of cyclobenzaprine. Archives of Internal Medicine, 160, 1373.Google Scholar

Duggal, H. S. & Singh, I. (2004). Worsening of psychosis or topiramate-induced adverse event. General Hospital Psychiatry, 26, 245–7.Google Scholar

Dunn, A. J., Wang, J., & Ando, T. (1999). Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Advances in Experimental Medicine & Biology, 461, 117–27.Google Scholar

Elko, C. J., Burgess, J. L., & Robertson, W. O. (1998). Zolpidem-associated hallucinations and serotonin reuptake inhibition: A possible interaction. Journal of Toxicology - Clinical Toxicology, 36, 195–203.Google Scholar

Evans, M., Perera, P. W., & Donoghue, J. (1997). Drug points: Drug induced psychosis with doxazosin. British Medical Journal, 314, 1869.Google Scholar

Fernandez, H. H., Trieschmann, M. E., Burke, M. A., Jaques, C., & Friedman, J. H. (2003). Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Movements Disorders, 18, 510–14.Google Scholar

Ferrie, C. D., Robinson, R. O., & Panayiotopoulos, C. P. (1996). Psychotic and severe behavioural reactions with vigabatrin: A review. Acta Neurologica Scandinavica, 93, 1–8.Google Scholar

Flores, B. H., Musselman, D. L., DeBattista, C., et al. (2004). Biology of mood disorders. In Textbook of Psychopharmacology, ed. Nemeroff, C. B., 3rd edn. Washington, DC: American Psychiatric Publishing, pp. 717–63.

Foster, R., Olajide, D., & Everall, I. P. (2003). Antiretroviral therapy-induced psychosis: Case report and brief review of the literature. HIV Medicine, 4, 139–44.Google Scholar

Friedman, J. H. (1991). The Management of the levodopa psychoses. Clinical Neuropharmacology, 14(4), 283–95.Google Scholar

Fuller, S. J., Naraqi, S., & Gilessi, G. (2002). Paranoid psychosis related to mefloquine antimalaria; prophylaxis. Papua New Guinea Medical Journal, 45, 219–21.Google Scholar

Garcia-Pares, G., Domenech, C., & Gil, M. (2002). Psychosis induced by interferon alpha, Psychosomatics, 43(5), 428.Google Scholar

Gatzonis, S. D., Angelopoulos, E.Sarigiannis, P., et al. (2003). Acute psychosis due to treatment with phenytoin in a nonepileptic patient. Epilepsy & Behavior, 4, 771–2.Google Scholar

Giupponi, G. & Erfurth, A. (1998). Transient psychosis in lisinopril-induced hyponatremia. Psychiatrische Praxis, 25, 204.Google Scholar

Golden, R. N., James, S. P., Sherer, M. A., et al. (1985). Psychoses associated with bupropion treatment. American Journal of Psychiatry, 142, 1459–62.Google Scholar

Goodman, A. B. (1998). Three independent lines of evidence to suggest retinoids as causal to schizophrenia. Proceedings of the National Academy of Science, 95, 7240–4.Google Scholar

Gopel, C., Laufer, C., & Marcus, A. (2002). Three cases of angel's trumpet tea-induced psychosis in adolescent substance abusers. Nordic Journal of Psychiatry, 56, 49–52.Google Scholar

Gordon, A. G. (1994). Musical hallucinations. Neurology, 44, 986–7.Google Scholar

Hall, R. C., Popkin, M. K., & Kirkpatrick, B. (1978). Tricyclic exacerbation of steroid psychosis. Journal of Nervous & Mental Disease, 166, 738–42.Google Scholar

Halpert, A. G., Olmstead, M. C., & Beninger, R. J. (2002). Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neuroscience & Biobehavioral Reviews, 26, 61–7.Google Scholar

Harsch, H. H. (1984). Mania in two patients following cyclobenzaprine. Psychosomatics, 25, 791–3.Google Scholar

Havaldar, P. V. & Mogale, K. D. (2000). Mefloquine-induced psychosis. Pediatric Infectious Disease Journal, 19(2), 166–7.Google Scholar

Hawkey, C. J. (1999). COX-2 inhibitors. Lancet, 353, 307–14.Google Scholar

Hemmingsen, R. & Rafaelsen, O. J. (1980). Hypnagogic and hypnopompic hallucinations during amitriptyline treatment. Acta Psychiatrica Scandinavica, 62, 364–8.Google Scholar

Hernandez, R., Juan, O., & Alberola, V. (2004). Ifosfamide-induced pyschosis. Acta Oncologica, 43, 119–20.Google Scholar

Hersh, C. B., Sokol, M. S., & Pfeffer, C. R. (1991). Transient psychosis with fluoxetine. Journal of the Academy of Child & Adolescent Psychiatry, 30, 851–2.Google Scholar

Hoffman, R. G., Cohen, M. A., Alfonso, C. A., et al. (2003) Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics, 44(5), 417–20.Google Scholar

Howard, W. T. & Warnock, J. K. (1999). Bupropion-induced psychosis. American Journal of Psychiatry, 156, 2017–18.Google Scholar

Hudgens, R. W., Tanna, V. L., Harley, J. D., & Leary, D. J. Jr. (1966). Visual hallucinations with iminodibenzyl antidepressants. Journal of the American Medical Association, 198, 199–200.Google Scholar

Iqbal, N. & Praag, H. M. (1995). The role of serotonin in schizophrenia. European Neuropsychopharmacology, 5(Suppl.), 11–13.Google Scholar

Iraqi, A. H. (2003). A case report of paranoid delusion with venlafaxine use. Journal of the American Geriatrics Society, 51, 1045–6.Google Scholar

Jablonowski, K., Margolese, H. C., & Chouinard, G. (2002). Gabapentin-induced paradoxical exacerbation of psychosis in a patient with schizophrenia. Canadian Journal of Psychiatry, 47(10), 975–6.Google Scholar

Jan Wise, M. E., Mistry, K., & Reid, S. (2002). Drug points: Neuropsychiatric complications of nevirapine treatment. British Medical Journal, 324, 879.Google Scholar

Jiang, H. K. & Chang, D. M. (1999). Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: Five case reports. Clinical Rheumatology, 18, 339–45.Google Scholar

Jick, S. S., Kremers, H. M., & Vasilakis-Scaramozza, C. (2000). Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Archives of Dermatology, 136, 1231–6.Google Scholar

Jones, I. H., Stevenson, J., Jordan, A., et al. (1973). Pheniramine as a hallucinogen. Medical Journal of Australia, 1, 382–6.Google Scholar

Keller, S. & Frishman, W. H. (2003). Neuropsychiatric effects of cardiovascular drug therapy. Cardiology in Review, 11, 73–93.Google Scholar

Kendler, K. S., Gallagher, T. J., Abelson, J. M., & Kessler, R. C. (1996). Lifetime prevalence, demographic risk factors, and diagnostic vulnerability of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Archives of General Psychiatry, 53, 1022–31.Google Scholar

Khouzam, H. R., Donnelly, N. J., & Ibrahim, N. F. (1998). Psychiatric morbidity in HIV patients. Canadian Journal of Psychiatry, 43, 51–6.Google Scholar

Kieburtz, K. D., Epstein, L. G., Gelbard, H. A., & Greenamyre, J. T. (1991). Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Archives of Neurology, 48, 1281–4.Google Scholar

Kim, D. (2000). A case of suspected alphagan-induced psychosis. Archives of Ophthalmology, 118, 1132–3.Google Scholar

Klein-Schwartz, W. (2002). Abuse and toxicity of methylphenidate. Current Opinion in Pediatrics, 2, 219–23.Google Scholar

Kukoyi, O. & Carney, C. P. (2003). Curses, madness, and mefloquine. Psychosomatics, 44(4), 339–41.Google Scholar

Kumagai, R., Ohnuma, T., Nagata, T., & Arai, H. (2003). Visual and auditory hallucinations with excessive intake of paroxetine. Psychiatry & Clinical Neurosciences, 57, 548–9.Google Scholar

Kurlan, R. & Dimitsopulos, T. (1992). Selegiline and manic behavior in Parkinson's disease, Archives of Neurology, 49, 1231.Google Scholar

Kuzuhara, S. (2001). Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma. Journal of Neurology, 248(Suppl. 3), III/28–31.Google Scholar

Lamps, C. A. (2002). Citalopram and psychotic symptoms. Journal of the American Academy of Child & Adolescent Psychiatry, 41, 6.Google Scholar

Lantz, M. S. & Giambanco, V. R. (2000). Acute onset of auditory hallucinations after initiation of celecoxib therapy. American Journal of Psychiatry, 157, 1022–3.Google Scholar

Lipowski, Z. J. (1990). Delirium: Acute Confusional States. New York: Oxford University Press.

Lissoni, P., Messina, G., Vaghi, M., et al. (2003). A psychoneuroendocrine study of brain dopaminergic sensitivity in locally limited or metastatic cancer patients. In Vivo, 17(6), 647–50.Google Scholar

Lu, M. L., Pan, J. J., Teng, H. W., Su, K. P., & Shen, W. W. (2002). Metoclopramide-induced supersensitivity psychosis. Annals of Pharmacotherapy, 36, 1387–90.Google Scholar

Major, L. F., Lerner, P., Ballenger, J. C., et al. (1979). Dopamine-beta-hydroxylase in the cerebrospinal fluid: Relationship to disulfram-induced psychosis. Biological Psychiatry, 14, 337–44.Google Scholar

Marcon, G., Cancelli, I., Zamarian, L., Bergonzi, P., & Balestrieri, M. (2004). Visual hallucinations with sertraline. Journal of Clinical Psychiatry, 65, 446–7.Google Scholar

Markowitz, J. S. & Brewerton, T. D. (1996). Zolpidem-induced psychosis. Annals of Clinical Psychiatry, 8, 89–91.Google Scholar

Markowitz, J. S., Rames, L. J., Reeves, N., & Thomas, S. G. (1997). Zolpidem and hallucinations. Annals of Emergency Medicine, 29, 300–1.Google Scholar

Merimsky, O., Reider-Groswasser, I., Wigler, N., & Chaitchik, S. (1992). Encephalopathy in ifosfamide-treated patients. Acta Neurologica Scandinavica, 86, 521–4.Google Scholar

Messina, G., Lissoni, P., Bartolacelli, E., et al. (2003). A psychoncological study of lymphocyte subpopulations in relation to pleasure-related neurobiochemistry and sexual and spiritual profile to Rorschach's test in early or advanced cancer patients. Journal of Biological Regulators & Homeostatic Agents, 17(4), 322–6.Google Scholar

Milgrom, H. & Bender, B. (1997). Adverse effects of medications for rhinitis. Annals of Allergy, Asthma, & Immunology, 78, 439–44.Google Scholar

Mirin, S. M., Schatzberg, A. F., & Creasey, D. E. (1981). Hypomania and mania after withdrawal of tricyclic antidepressants. American Journal of Psychiatry, 138, 87–9.Google Scholar

Mula, M., Trimble, M. R., Yuen, A., Liu, R. S. N., & Sander, J. W. A. S. (2003). Psychiatric adverse events during levetiracetam therapy. Neurology, 61, 704–6.Google Scholar

Muley, M. P., Joshi, M. A., & Manekar, M. S. (1984). Effect of bupropion on dopamine and 5-hydroxytryptamine-mediated behaviour in mice. Journal of Pharmacy & Pharmacology, 36, 208–10.Google Scholar

Murthy, K. K. (1997). Psychosis during disulfram therapy for alcoholism. Journal of the Indian Medical Association, 95, 80–1.Google Scholar

Narayan, M., Meckler, L., & Nelson, J. C. (1995). Fluoxetine-induced delusions in psychotic depression. Journal of Clinical Psychiatry, 56, 329.Google Scholar

Nelson, J. C., Bowers, M. B. Jr., & Sweeney, D. R. (1979). Exacerbation of psychosis by tricyclic antidepressants in delusional depression. American Journal of Psychiatry, 136, 574–6.Google Scholar

Nielsen, B., Nielsen, A., Sogaard, M., & Wraae, O. (2000). Factors associated with compliance of alcoholics in outpatient treatment. Journal of Nervous and Mental Disease, 188(2), 101–7.Google Scholar

Norra, C., Skobel, E., Brerer, C., et al. (2003). Ciprofloxacin-induced acute psychosis in a patient with multidrug-resistant tuberculosis. European Psychiatry, 18, 262–3.Google Scholar

O'Connel, G. J., Campbell, P. B., & Anath, J. V. (1972). Amitriptyline: Initial intolerance and subsequent psychosis. Canadian Medical Association Journal, 106, 115.Google Scholar

O'Donnell, J. (2003). Overview of existing research and information linking isotretinoin (accutane), depression, psychosis, and suicide. American Journal of Therapeutics, 10(2), 148–59.Google Scholar

Pallone, K. A., Goldman, M. P., & Fuller, M. A. (1993). Isoniazid-associated psychosis: Case report and review of the literature. The Annals of Phamacotherapy, 27, 167–70.Google Scholar

Patterson, J. F. (1984). Psychosis after discontinuation of nortriptyline. Journal of Clinical Psychopharmacology, 4, 117–18.Google Scholar

Pfeffer, F. & Grube, M. (2001). An organic psychosis due to a venlafaxine-propafenone interaction. International Journal of Psychiatry in Medicine, 31, 427–32.Google Scholar

Popli, A. P., Fuller, M. A., & Jaskiw, G. E. (1997). Sertraline and psychotic symptoms: A case series. Annals of Clinical Psychiatry, 9, 15–17.Google Scholar

Poulsen, H. D. & Lublin, H. K. F. (2003). Efavirenz-induced psychosis leading to involuntary detention. AIDS, 17(3), 451–3.Google Scholar

Prakash, R., Campbell, T. W., & Petrie, W. M. (1983). Psychoses with propranolol: A case report. Canadian Journal of Psychiatry, 28, 658–9.Google Scholar

Preda, A., MacLean, R. W., Mazure, C. M., & Bowers, M. B. Jr. (2001). Antidepressant-associated mania and psychosis resulting in psychiatric admissions. Journal of Clinical Psychiatry, 62, 30–3.Google Scholar

Quail, M. & Karelse, R. H. (1980). Disulfram psychosis. South African Medical Journal, 57, 551–2.Google Scholar

Rabinowitz, I. & Reis, S. (2001). Doctor, there's a fly in my soup! Angiotensin-converting enzyme inhibitors, endogenous opioids and visual hallucination. Israeli Medical Association Journal, 3, 963–4.Google Scholar

Rozzini, R., Inzoli, M., & Trabucchi, M. (1988). Delirium from transdermal scopolamine in an elderly woman. Journal of the American Medical Association, 260(4), 478.Google Scholar

Rundell, J. R. & Murray, G. B. (1988). Visual hallucinations on low dose amitriptyline. Journal of Clinical Psychopharmacology, 8, 75–6.Google Scholar

Schuld, A., Archelos, J. J., & Friess, E. (2000). Visual hallucinations and psychotic symptoms during treatment with selective serotonin reuptake inhibitors: Is the sigma receptor involved?Journal of Clinical Psychopharmacology, 20, 579–80.Google Scholar

Sewell, D. D., Jeste, D. V., Atkinson, J. H., et al. (1994). HIV-associated psychosis: A study of 20 cases. San Diego HIV Neurobehavioral Research Center Group. American Journal of Psychiatry, 151, 237–42.Google Scholar

Shepherd, G., Velez, L. I., & Keyes, D. C. (2004). Intentional bupropion overdoses. Journal of Emergency Medicine, 27, 147–51.Google Scholar

Shiovitz, T. M., Welke, T. L., Tigel, P. D., et al. (1996). Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophrenia Bulletin, 22(4), 591–5.Google Scholar

Sim, F. H. & Massabki, R. A. (2000). A single dose of fluvoxamine associated with an acute psychotic reaction. Canadian Journal of Psychiatry, 45, 762.Google Scholar

Sirois, F. (2003). Steroid psychosis: A review. General Hospital Psychiatry, 25, 27–33.Google Scholar

Smith, M. J. & Khayat, D. (1992). Residual acute confusional and hallucinatory syndromes induced by interleukin-2/alpha-interferon treatment. Psycho-Oncology, 1, 115–18.Google Scholar

Sowunmi, A., Adio, R. A., Oduola, A. M., Ogundahunsi, O. A., & Salako, L. A. (1995). Acute psychosis after mefloquine. Report of six cases. Tropical and Geographical Medicine, 47(4), 179–80.Google Scholar

Speich, R. & Haller, A. (1994). Central anticholinergic syndrome with the antimalarial drug mefloquine. New England Journal of Medicine, 331, 57–8.Google Scholar

Spigset, O. (1999). Adverse reactions of selective serotonin reuptake inhibitors: Reports from a spontaneous reporting system. Drug Safety, 20, 277–87.Google Scholar

Steinhert, J. & Pugh, C. R. (1979). Two patients with schizophrenic-like psychosis after treatment with beta-adrenergic blockers. British Medical Journal, 1(6166), 790.Google Scholar

Sternbach, H. & State, R. (1997). Antibiotics: Neuropsychiatric effects and psychotropic interactions. Harvard Review of Psychiatry, 5, 214–26.Google Scholar

Stevinson, C. & Ernst, E. (2004). Can St. John's wort trigger psychoses?International Journal of Clinical Pharmacology & Therapeutics, 42, 473–80.Google Scholar

Tamam, L., Yerdelen, D., & Ozpoyraz, N. (2003). Psychosis associated with interferon alfa therapy for chronic hepatitis B, Annals of Pharmacotherapy, 37, 384–7.Google Scholar

Tarlow, M. M., Sakaris, A., Scoyoni, R., & Wolf-Klein, G. (2000). Quinopril-associated acute psychosis in an older woman. Journal of the American Geriatrics Society, 48, 1533.Google Scholar

Terao, T. (1995). Tricyclic-induced musical hallucinations and states of relative sensory deprivation. Biological Psychiatry, 38, 192–3.Google Scholar

The Parkinson Study Group (1999). Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease: The parkinson study group. New England Journal of Medicine, 340, 757–63.

Timnak, C. & Gleason, O. (2004). Promethazine-induced psychosis in a 16-year-old girl. Psychosomatics, 45, 89–90.Google Scholar

Trimble, M. R. (1996). Anticonvulsant-induced psychiatric disorders. The role of forced normalization. Drug Safety, 15(3), 159–66.Google Scholar

Tripathi, A., Chen, S. I., & O'Sullivan, S. (2002). Acute psychosis following the use of topical ciprofloxacin. Archives of Ophthalmology, 120, 665–6.Google Scholar

Trepacz, P. T. (2000). Is there a common neural pathway in delirium? Focus on acetylcholine and dopamine. Seminars in Clinical Neuropsychiatry, 5(2), 132–48.Google Scholar

Trepacz, P. T. & Meagher, D. J. (2005). Delirium. In Textbook of Psychosomatic Medicine, ed. Levenson, J. L.. Washington, DC: American Psychiatric Publishing, pp. 91–130.

Ueda, N., Terao, T., Ohmori, O., & Nakamura, J. (2003). Schneiderian first-rank symptoms associated with fluvoxamine treatment: A case report. Human Psychopharmacology, 18, 477–8.Google Scholar

Uzych, L. (1992). Anabolic-androgenic steroids and psychiatric-related effects: A review. Canadian Journal of Psychiatry, 37, 23–8.Google Scholar

Muhlendahl, K. E. & Krienke, E. G. (1978). Toxicity of cyproheptadine. Side effects and accidental overdosage (author's transl.). GermanMonatsschrift fur Kinderheilkunde, 126, 123–6.Google Scholar

Walton, R. & Manos, G. H. (2003). Psychosis related to ephedra-containing herbal supplement use. Southern Medical Journal, 96, 718–20.Google Scholar

Wang, T. S., Shiah, I. S., Yeh, C. B., & Chang, C. C. (2005). Acute psychosis following sustained release bupropion overdose. Progress in Neuropsychopharmacology and Biological Psychiatry, 29(1), 149–51.Google Scholar

Watemberg, N. M., Roth, K. S., Alehan, F. K., & Epstein, C. E. (1999). Central anticholinergic syndrome on therapeutic doses of cyproheptadine. Pediatrics, 103, 158–60.Google Scholar

Webb, A. & Cranswick, N. (2003). Fluoxetine induced auditory hallucinations in an adolescent. Journal of Paediatrics & Child Health, 39, 637–8.Google Scholar

Wilkaitis, J., Mulvihill, T., & Nasrallah, H. (2004). Classic antipsychotic medications. In Textbook of Psychopharmacology, ed. Nemeroff, C. B., 3rd edn. Washington, DC: American Psychiatric Publishing, pp. 425–41.

Yassa, R. Y. & Iskandar, H. L. (1988). Baclofen-induced psychosis: Two cases and a review. Journal of Clinical Psychiatry, 49(8), 318–20.Google Scholar

Yi Chau, S. & Chiu Mok, C. (2003). Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology, 61(1), 104–7.Google Scholar

Young, B. K., Camicioli, R., & Ganzini, L. (1997). Neuropsychiatric adverse effects of antiparkinsonian drugs. Drugs and Aging, 10(5), 367–83.Google Scholar

Zifko, U. A., Rupp, M., Schwarz, S., Zipko, H. T., & Maida, E. M. (2002). Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. Journal of Neurology, 249(8), 983–7.Google Scholar